Estudios
I+D+I
Institución
Internacional
Vida Universitaria
Universidad de Zaragoza Repository
Search
Submit
Personalize
Your alerts
Your baskets
Your searches
Help
EN
/
ES
Home
>
Articles
> DD04107-Derived neuronal exocytosis inhibitor peptides: Evidences for synaptotagmin-1 as a putative target
Usage statistics
Plots
DD04107-Derived neuronal exocytosis inhibitor peptides: Evidences for synaptotagmin-1 as a putative target
Butrón D.
;
Zamora-Carreras H.
;
Devesa I.
;
Treviño M.A.
;
Abian O.
(Universidad de Zaragoza)
;
Velázquez-Campoy A.
(Universidad de Zaragoza)
;
Bonache M.Á.
;
Lagartera L.
;
Martín-Martínez M.
;
González-Rodríguez S.
;
Baamonde A.
;
Fernández-Carvajal A.
;
Ferrer-Montiel A.
;
Jiménez M.Á.
;
González-Muñiz R.
Resumen:
The analgesic peptide DD04107 (Pal-EEMQRR-NH2) and its acetylated analogue inhibit a-calcitonin gene-related peptide (a-CGRP) exocytotic release from primary sensory neurons. Examining the crystal structure of the SNARE-Synaptotagmin-1(Syt1) complex, we hypothesized that these peptides could inhibit neuronal exocytosis by binding to Syt1, hampering at least partially its interaction with the SNARE complex. To address this hypothesis, we first interrogate the role of individual side-chains on the inhibition of a-CGRP release, finding that E1, M3, Q4 and R6 residues were crucial for activity. CD and NMR conformational analysis showed that linear peptides have tendency to adopt a-helical conformations, but the results with cyclic analogues indicated that this secondary structure is not needed for activity. Isothermal titration calorimetry (ITC) measurements demonstrate a direct interaction of some of these peptides with Syt1-C2B domain, but not with Syt7-C2B region, indicating selectivity. As expected for a compound able to inhibit a-CGRP release, cyclic peptide derivative Pal-E-cyclo[EMQK]R-NH2 showed potent in vivo analgesic activity, in a model of inflammatory pain. Molecular dynamics simulations provided a model consistent with KD values for the interaction of peptides with Syt1-C2B domain, and with their biological activity. Altogether, these results identify Syt1 as a potential new analgesic target. © 2021
Idioma:
Inglés
DOI:
10.1016/j.bioorg.2021.105231
Año:
2021
Publicado en:
Bioorganic Chemistry
115 (2021), 105231
ISSN:
0045-2068
Factor impacto JCR:
5.307 (2021)
Categ. JCR:
CHEMISTRY, ORGANIC
rank: 8 / 57 = 0.14
(2021)
- Q1
- T1
Categ. JCR:
BIOCHEMISTRY & MOLECULAR BIOLOGY
rank: 99 / 297 = 0.333
(2021)
- Q2
- T2
Factor impacto CITESCORE:
7.1 -
Pharmacology, Toxicology and Pharmaceutics
(Q1) -
Biochemistry, Genetics and Molecular Biology
(Q2)
Factor impacto SCIMAGO:
0.728 -
Biochemistry
(Q2) -
Molecular Biology
(Q2) -
Drug Discovery
(Q2)
Tipo y forma:
Article (Published version)
Área (Departamento):
Área Bioquímica y Biolog.Mole.
(
Dpto. Bioq.Biolog.Mol. Celular
)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Exportado de SIDERAL (2023-05-18-15:41:35)
Permalink:
Copy
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Back to search
Record created 2022-08-17, last modified 2023-05-19
Versión publicada:
PDF
Rate this document:
Rate this document:
1
2
3
4
5
(Not yet reviewed)
Add to personal basket
Export as
BibTeX
,
MARC
,
MARCXML
,
DC
,
EndNote
,
NLM
,
RefWorks